Img header logo

ESG Data

アンカーリンク用

Regarding the data for FY2022 marked with , we have received independent assurance in our SUSTAINABILITY DATA 2023 (PDF version) so as to bolster the reliability of the information. For details, please see the “Independent Practitioner's Assurance.”Governance Data

ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system

Governance Data

Corporate Governance
Item Scope Unit FY2018 FY2019 FY2020 FY2021 FY2022
Board structure Directors (Total) Non-consolidated Persons 8 8 8 8 8
Independent outside directors Non-consolidated Persons 3 3 3 3 3
Female directors Non-consolidated Persons 0 0 1 1 1
Board of Auditors structure Auditors (Total) Non-consolidated Persons 4 4 4 4 4
Independent outside auditors Non-consolidated Persons 2 2 2 2 2
Female auditors Non-consolidated Persons 1 1 1 1 1
Director Remuneration Total Non-consolidated Million yen 360 368 384 428 595*1
President, Representative Director, and Chief Executive Officer Non-consolidated Million yen 114 116 126 125 227*1
Auditor Remuneration Total Non-consolidated Million yen 77 78 83 85 90
Number of Board of Directors meetings Non-consolidated Times 13 13 13 15 12
Number of Board of Auditors meetings Non-consolidated Times 14 14 19 16 15
Board attendance rate(directors) Non-consolidated % 100 100 98.6 100 100
Board attendance rate(auditors) Non-consolidated % 100 92.3*2 100 100 97.9
  • In FY2022, the remuneration system for Members of the Board of Directors was revised. The previous stock-based remuneration-type stock option system was abolished, and the restricted stock-based remuneration system was introduced. As a transitional measure, restricted stocks (75,000 shares) were issued to the Members of the Board of Directors in lieu of abandoning all stock options that had been allocated but not yet exercised (equivalent to 75,000 shares). The "Total" and the "President, Representative Director, and Chief Executive Officer" of Director Remuneration above included the difference between the amount equivalent to the abandoned stock options and the amount included in the costs in FY2022 when the restricted stocks were issued (96 million yen (for the "Total") and 51 million yen (for the "President, Representative Director, and Chief Executive Officer").
  • The attendance rate of Audit & Supervisory Board Members excluding the Audit & Supervisory Board Member who resigned due to illness on March 27, 2020 was 100%.
Compliance
Item Scope Unit FY2018 FY2019 FY2020 FY2021 FY2022
Compliance training attendance rate Non-consolidated % 100 100 100 100 100
Number of reports Bribery cases Non-consolidated Incidents 0 0 0 0 0
Discrimination and harassment related Non-consolidated Incidents - 22 15 29 22
Personnel and labor management related Non-consolidated Incidents - 2 1 2 6
Customer privacy data related Non-consolidated Incidents - - - - 0
Conflicts of interest related Non-consolidated Incidents - - - - 0
Money laundering or Insider trading related Non-consolidated Incidents - - - - 0
Others Non-consolidated Incidents - 44 6 29 22
Total Non-consolidated Incidents 44 68 22 60 50
Number of compliance violations(Disciplinary action cases) Bribery cases Non-consolidated Incidents 0 0 1 0 0
Discrimination and harassment related Non-consolidated Incidents - 3 1 0 4
Personnel and labor management related Non-consolidated Incidents - 0 0 1 0
Customer privacy data related Non-consolidated Incidents - - - - 0
Conflicts of interest related Non-consolidated Incidents - - - - 0
Money laundering or Insider trading related Non-consolidated Incidents - - - - 0
Others Non-consolidated Incidents - 6 0 10 9
Total Non-consolidated Incidents 5 9 2 11 13
Costs for legal violations Non-consolidated Million yen - - 0 0 0
Number of facilitation payments Non-consolidated Incidents 0 0 0 0 0
ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system

Social Data

ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system

Environmental Data

Overall Picture of Environmental Impact (ONO's Involvement in Environmental Protection)

Annual inputs and outputs are grasped on a regular basis to use as reference data for our efforts to reduce environmental impact (FY2022).

figure
  • Sites where data were collected: [Non-consolidated] Fujiyama Plant, Joto Pharmaceutical Product Development Center, Yamaguchi Plant, Minase Research Institute, Fukui Research Institute, Tsukuba Research Institute, Head Office, sales offices and other offices, etc. (logistics centers have been added from FY2021 only for waste data)
    [Group companies] ONO PHARMA USA, INC., Cambridge, ONO PHARMA UK LTD, London, ONO PHARMA KOREA CO., LTD, Seoul, ONO PHARMA TAIWAN CO., LTD. Taipei, and Ono Pharma UD Co., Ltd.
GHG emissionsSince the figures in the table are rounded, the breakdown totals may not
always coincide with the overall totals (same as environmental data below).
Item Scope Unit FY2018 FY2019 FY2020 FY2021 FY2022
GHG emissions scope breakdown (Market-basis)  (a) Scope 1 (Breakdown by GHG type) Energy-derived Non-consolidated kt-CO2 9.0 9.7 10.0 9.8 8.0
Group Companies - - - - 0.0
Non-energy-derived (HFCs, HCFCs) Non-consolidated 0.5 0.4 0.1 0.03 0.2
Group Companies - - - - 0.0
Total - - - - 8.2
Scope 2 Non-consolidated kt-CO2 19.1 17.1 15.9 13.7 10.2
Group Companies - - - - 0.1
Total - - - - 10.4
Scope 1+2 (Total) Non-consolidated kt-CO2 28.5 27.3 26.1 23.6 18.4
Group Companies - - - - 0.1
Total - - - - 18.6
Amount of CO2 offset due to voluntary credit(Carbon-neutral city gas purchased) (b) Non-consolidated kt-CO2 - - - 0.6 0.7
GHG emissions after offset (a-b) Subtotal (Non-consolidated) kt-CO2 - - - 23.0 17.7
Total - - - - 17.9
  • GHG emissions are calculated using the following formula.
    [Domestic sites] GHG emissions = Purchased electricity × Adjusted emission factor published by electric power company + Σ (Fuel consumption × Unit calorific value × Carbon emission factor × 44/12) + Σ (Fluorocarbon leakage amount × Global warming potential)
    [Overseas sites] Calculated by multiplying the amount of electricity purchased at overseas sites by the electric utility company's emission factor or the country-specific emission factor published by the IEA.
    The amount of green electric power certified under the Green Energy Certificate and , the amount of renewable energy certified under the J-Credit Scheme and the Non-Fossil Fuel Certificate quota are deducted.
GHG emissions in the supply chain (Scope3)
Category Calculation method Notes Scope Unit FY2018 FY2019 FY2020 FY2021 FY2022
C1 Purchased goods and services GHG emissions (scope  1,2) volume of our major suppliers of raw materials and materials (accounting for 80% or more of our raw materials or materials purchase costs) multiplied by the ratio of the sales to ONO out of the total sales of the supplier. Ratios for other business suppliers are assumed to follow the same trend as for major suppliers, and are calculated using the ratio of GHG emissions to the transaction amount at major suppliers. ·This category is closely associated with our business activities since active pharmaceutical ingredients for manufacturing of drugs, intermediate products and research reagents are included.
·Covers production and research sites
Non-consolidated kt-CO2 8.1 11.5 12.7 13.8 -
C2 Capital goods Amount of capital goods treated as fixed assets (reinforcement of facilities/maintenance investment) excluding land, multiplied by factor Calculated based on capital goods treated as fixed assets. The fixed assets used in this calculation are essential for business activities. kt-CO2 60.4 26.9 25.8 26.4 21.3
C3 Fuel- and energy-related activities not included in scope 1 or scope 2 Amount of non-renewable electricity purchased, multiplied by emission factor - kt-CO2 1.5 2.8 2.7 2.4 2.1
C4 Upstream transportation and distribution Transport data on deliveries from our production sites and distribution centers to destinations, multiplied by emission factor - kt-CO2 0.1 0.1 0.1 0.1 0.1
C5 Waste generated in operations Weight of each type of industrial waste generated, multiplied by emission factor - kt-CO2 0.3 0.3 0.3 0.3 0.3
C6 Business travel Business travel costs, multiplied by emission factor Covers travels by airplane or Shinkansen bullet train kt-CO2 2.3 4.0 0.4 0.5 1.3
C7 Employee commuting Commuting costs, multiplied by emission factor 'Includes the amount for commuting by car from 2021 kt-CO2 0.4 0.5 0.4 0.7 0.7
C8 Upstream leased assets Fuel consumption used in leased vehicles, multiplied by emission factor - kt-CO2 3.3 2.9 2.0 2.1 1.9
C9 Downstream transportation and distribution GHG emissions on our major pharmaceutical wholesalers, multiplied by percentage of our net sales included in all net sales of major pharmaceutical wholesalers ·Transportation and distribution are important business activities to control distribution of and to ensure stable supply of drugs. kt-CO2 5.3 4.9 5.0 5.5 -
C10 Processing of sold products - We make only finished products kt-CO2 Not relevant Not relevant Not relevant Not relevant Not relevant
C11 Use of sold products - No energy is consumed during the use of ONO products Not relevant Not relevant Not relevant Not relevant Not relevant
C12 End-of-life treatment of sold products Weight of each type of our product container or packaging disposed of as waste, multiplied by emission factor - kt-CO2 0.2 0.2 0.2 0.1 0.2
C13 Downstream leased assets Floor space of asset (building) owned and rented out categorized by use, multiplied by emission factor - kt-CO2 0.3 0.3 0.3 0.3 0.3
C14 Franchises - ONO does not operate franchises kt-CO2 Not relevant Not relevant Not relevant Not relevant Not relevant
C15 Investments - There is no investment involving large amounts of greenhouse gas emissions. kt-CO2 Not relevant Not relevant Not relevant Not relevant Not relevant
Total kt-CO2 82.2 54.4 49.8 52.3 -
  • The emission factors used for calculation are figures stated in the "Emission Factor Database on Accounting for Greenhouse Gas Emissions throughout the Supply Chain (FY2018, Ver. 2.6;
    FY2019, Ver. 3.0; FY2020, Ver. 3.1; FY2021, Ver. 3.2; FY2022, Ver. 3.3)," published by the Ministry of the Environment, Government of Japan.
    Categories 1 and 9 and their total for FY2022 are not calculated because our major suppliers and pharmaceutical wholesalers had not published their GHG at the time of calculation.
    Only category 2 is consolidation.
Energy consumption
Item Scope Unit FY2018 FY2019 FY2020 FY2021 FY2022
Energy consumption Non-consolidated MWh 93,763.8 101,605.6 103,204.3 99,499.9 86,067.6
Group Companies - - - - 344.1
Total - - - - 86,411.7
Total electricity consumption and share of renewable energy
Item Scope Unit FY2018 FY2019 FY2020 FY2021 FY2022
Electricity consumption Private power generation (renewable) (solar power generation) Non-consolidated MWh 65.0 63.0 63.3 61.9 64.4
Group Companies - - - - 0.0
Purchased electricity (renewable) (Non-fossil fuel) Non-consolidated - 1,278.0 1,954.7 2,040.0 3,480.0
Group Companies - - - - 0.0
Private power generation (non-renewable) Non-consolidated 8,856.2 8,185.3 8,566.3 8,283.7 7,285.0
Group Companies - - - - 0.0
Purchased electricity (non-renewable) Non-consolidated 43,734.4 46,351.7 45,232.2 42,833.5 37,821.6
Group Companies - - - - 343.7
Subtotal
(Non-consolidated total electricity consumption)
52,655.5 55,878.0 55,816.5 53,219.2 48,651.0
Total (total electricity consumption) - - - - 48,994.7
Amount of credits purchased Solar power generation Fujiyama Plant/Tsukuba Research Institute/Fukui Research Institute/Sales offices and other offices MWh - 2,427.0 4,946.6 3,937.9 0.0
Biomass power generation 2,900.0 2,460.9 386.2 3,000.0 6,907.0
Renewable energy usage* Total MWh 2,965.0 6,228.9 7,350.7 9,039.9 10,451.4
Renewable energy usage rate (renewable energy usage / total electricity consumption) Subtotal
(Non-consolidated)
5.6 11.1 13.2 17.0 21.5
Total - - - - 21.3
  • Renewable energy usage = Private power generation (renewable) + Purchased electricity (renewable) + Amount of credits purchased
Water intake and wastewater volume by site (unit: 1,000 m3)
Site name River in the area Wastewater drainage destination FY2018 FY2019 FY2020 FY2021 FY2022
Water intake volume Wastewater volume Water intake volume Wastewater volume Water intake volume Wastewater volume Water intake volume Wastewater volume Water intake volume Wastewater volume
Fujiyama Plant Fuji River River 240.2 178.4 185.0 145.1 157.8 125.0 138.7 110.2 122.9 100.1
Joto Pharmaceutical Product Development Center Yodo River Sewer 6.0 6.0 5.1 5.1 4.6 4.6 3.9 3.9 22.8 20.9
Yamaguchi Plant Fushino River River 8.2 8.2 18.1 18.1 18.6 17.7 21.6 20.0 3.4 3.4
Minase Research Institute Yodo River Sewer 41.2 41.2 39.1 39.1 33.7 33.7 31.5 31.5 32.2 32.2
Fukui Research Institute Kuzuryu River Sewer 31.3 5.0 27.3 5.7 13.7 2.6 6.6 1.9 0.8 0.2
Tsukuba Research Institute Lake Kasumigaura Sewer 6.0 6.0 7.1 7.1 7.2 7.2 7.0 7.0 4.7 4.7
Head Office and other sites in Japan (including tenant locations) Rivers/lake in the areas around each business site* Sewer 15.1 15.1 15.0 15.0 10.0 10.0 10.0 10.0 9.5 9.5
Total 348.0 259.9 296.7 235.2 245.6 200.8 219.4 184.5 196.4 171.2
  • Major basins: Toyohira River, Okura River, Arakawa River, Sakawa River, Kiso River, Lake Biwa, Yodo River, Ota River, Yoshino River, Naka River
Waste Management, and Recycling Containers and Product Packaging
Item Scope Unit FY2018 FY2019 FY2020 FY2021 FY2022
Industrial waste Waste generated Non-consolidated t 446.4 430.8 502.7 479.1 492.8
[Waste breakdown]
Special management industrial waste (hazardous waste)*
t 145.6 161.9 171.2 170.3 142.5
final landfill disposal t 0.4 0.2 1.1 0.2 0.1
final landfill disposal rate % 0.1 0.1 0.2 0.04 0.02
final landfill disposal (Non-industrial waste is included) t 9.4 6.7 5.9 5.3 4.4
Container and packaging usage Plastic Non-consolidated t 171.7 162.8 161.5 147.0 173.4
Paper t 202.7 200.9 198.1 175.6 163.4
Glass (colorless) t 0.0 0.0 0.0 0.0 0.0
Glass (brown) t 0.3 0.3 0.2 0.2 0.2
Obligatory recycling amount Plastic t 35.5 31.2 35.1 36.6 52.2
Paper t 1.6 1.5 1.4 1.3 0.8
Glass (colorless) t 0.0 0.0 0.0 0.0 0.0
Glass (brown) t 0.0 0.0 0.0 0.0 0.0
Commissioning fee paid for recycling 1,000 yen 1,650 1,546 1,814 1,958 3,049
  • Special management industrial waste (hazardous waste) is defined under the Waste Management and Public Cleansing Law as waste that has properties of explosiveness, toxicity, infectiousness, and/or possibly causing damage to human health or the living environment.
Prevention of Air Pollution and Water Pollution
Item Scope Unit FY2018 FY2019 FY2020 FY2021 FY2022
Emissions into the air SOx Non-consolidated t 0.0 0.0 0.0 0.0 0.0
NOx t 8.4 8.1 8.1 8.3 4.9
Particulate matter t 0.28 0.33 0.32 0.34 0.26
PRTR substance t 0.25 0.15 0.35 0.32 0.28
Emissions into water Wastewater 1,000m3 244.8 220.2 190.8 174.5 171.2
BOD t 2.2 1.3 1.2 1.3 1.2
PRTR substance t 0.0 0.0 0.0 0.0 0.0
Management of Chemicals (PRTR substances)
Item Scope Unit FY2018 FY2019 FY2020 FY2021 FY2022
Amount handled by the notified facilities Acetonitrile Non-consolidated t 7.2 8.5 10.4 9.3 6.9
Normal-hexane t 2.8 3.0 2.6 2.3 1.8
Total t 10.0 11.5 13.0 11.6 8.7
Dioxins mg-TEQ - - - - -
Notified release (into the air) Acetonitrile t 0.2 0.1 0.3 0.3 0.3
Normal-hexane t 0.0 0.0 0.0 0.0 0.0
Total t 0.2 0.1 0.3 0.3 0.3
Dioxins mg-TEQ - - - - -
Notified release (into public waters) Acetonitrile t 0.0 0.0 0.0 0.0 0.0
Normal-hexane t 0.0 0.0 0.0 0.0 0.0
Total t 0.0 0.0 0.0 0.0 0.0
Dioxins mg-TEQ - - - - -
Notified transfer (contained in waste) Acetonitrile t 6.9 8.4 10.1 8.9 6.6
Normal-hexane t 2.8 3.0 2.6 2.3 1.8
Total t 9.8 11.3 12.7 11.3 8.4
Dioxins mg-TEQ - - - - -
Notified transfer (Into public sewage) Acetonitrile t 0.0 0.0 0.0 0.0 0.0
Normal-hexane t 0.0 0.0 0.0 0.0 0.0
Total t 0.0 0.0 0.0 0.0 0.0
Dioxins mg-TEQ - - - - -
Notified release and transfer (total) Acetonitrile t 7.2 8.5 10.4 9.3 6.9
Normal-hexane t 2.8 3.0 2.6 2.3 1.8
Total t 10.0 11.5 13.0 11.6 8.7
Dioxins mg-TEQ - - - - -
Management of Chemicals (PCB)
Item Unit FY2018 FY2019 FY2020 FY2021 FY2022
In use Number of units 2 2 2 2 2
Stored PCB 552 0 0 0 0
  • In FY2019, 552 units of stored PCB-using equipment were properly disposed of by contractors licensed to dispose of PCBs.
Environmental Management
Item Scope Unit FY2018 FY2019 FY2020 FY2021 FY2022
Status of acquisition of ISO 14001 certification Non-consolidated site 100% 100% 100% 100% 100%
  • Scope of ISO 14001 certification at production sites.
Environmental Violations
Item Scope Unit FY2018 FY2019 FY2020 FY2021 FY2022
Number of breaches of legal obligation/regulatory violations Non-consolidated Cases 0 0 0 0 0
Amount of breach-/violation-related fines Million yen 0 0 0 0 0
Environmental liabilities as of fiscal year-end Million yen 0 0 0 0 0
  • Breach/violation cases with fines of USD 10,000 or more
    The above includes violations related to air and soil pollution, noise, vibration, and water quality.
ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system

Social Contribution Activities Data

Initiatives for medical advancement
Item Scope Unit FY2018FY2019 FY2020 FY2021 FY2022
Osamu Hayaishi Memorial Award - Persons 1 1 1 1 1
Recipients of theresearch grant - Persons 12 12 12 12 15
Recipients of theresearch scholarship grant(40 years old and below) - Persons 16 16 15 16 15
Recipients of the Osamu Hayaishi Memorial Scholarship for Study Abroad - Persons 8 8 8 8 8
ONO PHARMACEUTICAL CO.,LTD., ONO PHARMACEUTICAL CO.,LTD., system